Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Reversible ethambutol-induced optic neuropathy: report of a rare case

Universa Medicina · Vol. 41 No. 3 (2022) · hlm. 271–276

DOI
10.18051/UnivMed.2022.v41.271-276
ISSN
2407-2230, 1907-3062
Terbit
2022-08-13
Penerbit
Faculty of Medicine, Universitas Trisakti
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-nc-sa/4.0

Abstrak

BackgroundEthambutol (EMB) is one of the first-line anti-tuberculosis therapy. One of its precarious side effects is ethambutol-induced optic neuropathy (EON). The ocular manifestations of EON include painless loss of central vision and cecocentral scotomas in the visual field. Case DescriptionA 60-year old man presented with gradual and painless visual loss since 3 months prior to visit. The accompanying symptoms were frequent headache without double vision and photophobia. He had been diagnosed with pulmonary tuberculosis (TB) for 9 months and consumed EMB for 7 months before being advised to discontinue. There was neither history of systemic diseases nor family history of neuropathy. Examination showed reduced visual acuity with positive relative afferent pupillary defect (RAPD) on right eye. Humphrey test showed bilateral generalized visual loss. Ocular computed tomography (OCT) showed retinal nerve fiber layer (RNFL) thickness was within normal limit. Magnetic resonance Imaging (MRI) brain indicated unremarkable result for optic neuropathy. Based on the examinations listed above, this patient was diagnosed as EON and EMB was stopped immediately. Patient was given oral citicoline 1000mg and zinc supplementation for one month. After 1 st and 3 rd month follow up, patient’s visual function was gradually improved. The ophthalmic examinations indicated recovery of the visual function. ConclusionsThis case suggested that an early detection and intervention in patient with EON has promising result in visual outcome. EON is a reversible optic neuropathy if the ocular toxicity is monitored closely among the tuberculosis patients who are prescribed EMB regiment.

Kata kunci

Jaringan kolaborasi para penulis

9 penulis · 24 tautan kepenulisan bersama · 18 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Indonesia
  • University of Brawijaya
  • Universitas Hang Tuah
  • National Research and Innovation Agency
  • Udayana University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Anwar SantosoUdayana University1
Bambang Budi SiswantoUniversity of Indonesia1
Lutfah Rif’atiNational Research and Innovation Agency1
Wienta DiarsvitriUniversitas Hang Tuah1
Seskoati PrayitnaningsihUniversity of Brawijaya1
Virna Dwi OktarianaUniversity of Indonesia1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://univmed.org/ejurnal/index.php/medicina/oai, pertama di-harvest 10 Nov 2026, terakhir terlihat 16 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Reversible ethambutol-induced optic neuropathy:  report of a rare case</dc:title>
	<dc:creator xml:lang="en">Nusanti, Syntia</dc:creator>
	<dc:creator xml:lang="en">Putri, Rasyidia Laksmita</dc:creator>
	<dc:creator xml:lang="en">Dearaini, Dearaini</dc:creator>
	<dc:subject xml:lang="en">Ethambutol</dc:subject>
	<dc:subject xml:lang="en">optic neuropathy</dc:subject>
	<dc:subject xml:lang="en">toxic optic neuropathy</dc:subject>
	<dc:description xml:lang="en">BackgroundEthambutol (EMB) is one of the first-line anti-tuberculosis therapy. One of its precarious side effects is ethambutol-induced optic neuropathy (EON). The ocular manifestations of EON include painless loss of central vision and cecocentral scotomas in the visual field.
Case DescriptionA 60-year old man presented with gradual and painless visual loss since 3 months prior to visit. The accompanying symptoms were frequent headache without double vision and photophobia. He had been diagnosed with pulmonary tuberculosis (TB) for 9 months and consumed EMB for 7 months before being advised to discontinue. There was neither history of systemic diseases nor family history of neuropathy. Examination showed reduced visual acuity with positive relative afferent pupillary defect (RAPD) on right eye. Humphrey test showed bilateral generalized visual loss. Ocular computed tomography (OCT) showed retinal nerve fiber layer (RNFL) thickness was within normal limit. Magnetic resonance Imaging (MRI) brain indicated unremarkable result for optic neuropathy. Based on the examinations listed above, this patient was diagnosed as EON and EMB was stopped immediately. Patient was given oral citicoline 1000mg and zinc supplementation for one month. After 1 st and 3 rd month follow up, patient’s visual function was gradually improved. The ophthalmic examinations indicated recovery of the visual function.
ConclusionsThis case suggested that an early detection and intervention in patient with EON has promising result in visual outcome. EON is a reversible optic neuropathy if the ocular toxicity is monitored closely among the tuberculosis patients who are prescribed EMB regiment.</dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Universitas Trisakti</dc:publisher>
	<dc:date>2022-08-13</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://univmed.org/ejurnal/index.php/medicina/article/view/1274</dc:identifier>
	<dc:identifier>10.18051/UnivMed.2022.v41.271-276</dc:identifier>
	<dc:source xml:lang="en">Universa Medicina; Vol. 41 No. 3 (2022); 271-276</dc:source>
	<dc:source>2407-2230</dc:source>
	<dc:source>1907-3062</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://univmed.org/ejurnal/index.php/medicina/article/view/1274/711</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2022 Syntia Nusanti, Rasyidia Laksmita Putri, Dearaini Dearaini</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by-nc-sa/4.0</dc:rights>
</oai_dc:dc>